Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $64
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
Express News | As Consideration For Assets, UroGen Issued IconOVir 374,843 Of Its Ordinary Shares, Agreed To One-Time Payment Of $15M Upon Milestones And A Low Single-Digit Royalty Percentage
Express News | UroGen Acquires Assets Relating To ICVB-1042 From IconOVir
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
UroGen Pharma Coverage Assumed by Ladenburg Thalmann at Buy
Ladenburg Thalmann Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $31
UroGen Announces Subgroup Analysis Results For ENVISION Study Of UGN-102 In LG-IR-NMIBC; Comparable CR Rates And DOR Observed Across Tumor Burden And Focality Levels
UroGen Announces Results From Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Express News | D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
Insider Sale: Chief Medical Officer of $URGN Sells 1,896 Shares
UroGen Pharma to Present at Upcoming Investor Conferences
Express News | UroGen Highlights Results From Study On Durability Of Response From Post-Commercialization Of JELMYTO Titled 'Durability of Response of UGN-101: Longitudinal Follow-Up of Multicenter Study'
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population With Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Express News | UroGen Pharma Shares Are Trading Higher After the Company Reported Its ENVISION Trial Results in the February Issue of The Journal of Urology
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)
UroGen Pharma Is Maintained at Buy by D. Boral Capital